eligibility_summary
Adults ≥18 with advanced/metastatic solid tumors (e.g., NSCLC, colorectal, pancreatic, endometrial) harboring KRAS G12D and HLA-C08:02 plus HLA-A11:01/11:02, ≥1 prior SOC, measurable lesion, ECOG 0–1. Exclude: malignancy <3y, active primary CNS cancer, prior adoptive cell/gene therapy or allo transplant, recent stroke/TIA or cardiac disease, recent systemic therapy, immunodeficiency/active autoimmune on immunosuppression, lactation, KRAS agents unless G12D reconfirmed.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: NT-112 and AZD0240, both autologous TCR-engineered T-cell (TCR-T) therapies. NT-112 uses a transgenic TCR specific for the KRAS G12D neoantigen presented by HLA-C08:02, AZD0240 targets KRAS G12D presented by HLA-A11:01 or HLA-A11:02. Mechanism of action: infused TCR-T cells recognize the KRAS G12D peptide–HLA complex on tumor cells, triggering T-cell activation and cytotoxic killing. Targets: tumor cells harboring KRAS G12D mutations in solid tumors (NSCLC, colorectal, pancreatic ductal adenocarcinoma, endometrial). Pathways/cells: oncogenic KRAS-driven tumors, HLA class I antigen presentation and TCR signaling pathways, cytotoxic T lymphocyte effector function.